Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
03 February 2023Website:
http://structuretx.comNext earnings report:
07 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 22:27:39 GMTDividend
Analysts recommendations
Institutional Ownership
GPCR Latest News
A couple of analysts initiated coverage on Septerna, Inc. SEPN, which debuted on NASDAQ last month.
SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that management will participate in a presentation and fireside chat, and host one-on-one meetings at the Jefferies London Healthcare Conference being held November 19-21, 2024, in London, UK.
Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs).
SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced management will participate at the following investor conferences in September:
Structure Therapeutics (GPCR) is expected to provide updates on the developmental pathway of its lead product candidate, GSBR-1290, for diabetes and obesity indications in the Q2 earnings release.
There's always a strong case for undervalued biotech stocks. For one, the industry is only expected to grow.
Structure Therapeutics (GPCR) stock sees an upside on positive top-line data from a phase IIa obesity study as well as a capsule-to-tablet PK study on its obesity candidate, GSBR-1290.
Structure Therapeutics is a clinical-stage biotech developing a small-molecule drug that mimics an important gut hormone. Early results for Structure Therapeutics' lead candidate compare well with Wegovy and experimental weight management treatments.
Structure Therapeutics published some strong data from its weight-loss program. Its candidate preliminarily appears to be more effective than the market leader.
SAN FRANCISCO, June 07, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced the closing of its previously announced upsized underwritten public offering of 10,427,017 American depositary shares (ADSs), each representing three ordinary shares, including the full exercise of the underwriters' option to purchase up to 1,360,045 additional ADSs, at a public offering price of $52.50 per ADS. The aggregate gross proceeds to Structure Therapeutics from the offering were approximately $547.4 million, before deducting underwriting discounts and commissions and offering expenses. All of the ADSs were offered by Structure Therapeutics.
- 1(current)
What type of business is Structure Therapeutics American Depositary Shares?
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
What sector is Structure Therapeutics American Depositary Shares in?
Structure Therapeutics American Depositary Shares is in the Healthcare sector
What industry is Structure Therapeutics American Depositary Shares in?
Structure Therapeutics American Depositary Shares is in the Biotechnology industry
What country is Structure Therapeutics American Depositary Shares from?
Structure Therapeutics American Depositary Shares is headquartered in United States
When did Structure Therapeutics American Depositary Shares go public?
Structure Therapeutics American Depositary Shares initial public offering (IPO) was on 03 February 2023
What is Structure Therapeutics American Depositary Shares website?
https://structuretx.com
Is Structure Therapeutics American Depositary Shares in the S&P 500?
No, Structure Therapeutics American Depositary Shares is not included in the S&P 500 index
Is Structure Therapeutics American Depositary Shares in the NASDAQ 100?
No, Structure Therapeutics American Depositary Shares is not included in the NASDAQ 100 index
Is Structure Therapeutics American Depositary Shares in the Dow Jones?
No, Structure Therapeutics American Depositary Shares is not included in the Dow Jones index
When was Structure Therapeutics American Depositary Shares the previous earnings report?
No data
When does Structure Therapeutics American Depositary Shares earnings report?
The next expected earnings date for Structure Therapeutics American Depositary Shares is 07 March 2025